Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OsrhCT for Improving Mucosal Visualization Clarity During Gastroscopy
NCT07893600Phase 2Not yet recruiting
- Sponsor
- Wuhan Healthgen Biotechnology Corp.
- Start
- Oct 2026
- Primary completion
- Dec 2026
01
Overview
Phase 2, randomised, double-blind trial comparing Recombinant Human Chymotrypsin(OsrhCT) 12000U with Placebo for Recombinant Human Chymotrypsin(OsrhCT) (2 arms). Primary endpoint: Total visibility score up to 2 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Recombinant Human Chymotrypsin
Beyond the preview
Go deeper on NCT07893600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893600.